Related Experiment Video
Updated: Jun 15, 2025
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated
Gabriel Bsteh1, Marie L Aicher1, Janette F Walde1
1From the Department of Neurology (G.B., N.K., K.R., P.A., B.K., F.L., P.S.R., G.Z., T.Z., T.B.), and Comprehensive Center for Clinical Neurosciences & Mental Health (G.B., N.K., K.R., P.A., B.K., F.L., P.S.R., G.Z., T.Z., T.B.), Medical University of Vienna, Austria; Department of Neurology (M.L.A., A.S., A.C., R.H., H. Hammer), Inselspital, Bern University Hospital and University of Bern, Switzerland; Department of Statistics (J.F.W.), Faculty of Economics and Statistics, University of Innsbruck; Department of Biomedical Imaging and Image Guided Therapy (L.H.), Clinical Department of Neuroradiology and Musculoskeletal Radiology, Medical University of Vienna; Department of Neurology 2 (G.T.), Med Campus III, Kepler University Hospital GmbH, Linz; Department of Neurology (C.G.), Medical University of St. Pölten; and Departments of Neuroradiology (P.P.) and Neurology (P.L., M.A., K.B., F.D.P., F.D., H. Hegen), Medical University of Innsbruck, Austria.
Background And Objectives:
Isolated value of MRI metrics in relapsing multiple sclerosis (RMS) as a surrogate marker of response to disease-modifying treatment (DMT) and, thus, as decision criteria for DMT escalation in the absence of clinical signs of disease activity is still a matter of debate. The aim of this study was to investigate whether DMT escalation based on isolated MRI activity affects clinical outcome.
Methods:
Combining data from 5 MS centers in Austria and Switzerland, we included patients with RMS aged at least 18 years who (1) had initiated first-line, low-to-moderate-efficacy DMT (interferon β, glatiramer acetate, teriflunomide, or dimethyl fumarate) continued for ≥12 months, (2) were clinically stable (no relapses or disability progression) on DMT for 12 months, (3) had MRI at baseline and after 12 months on DMT, and (4) had available clinical follow-up for ≥2 years after the second MRI. The primary endpoint was occurrence of relapse during follow-up. The number of new T2 lesions (T2L) and DMT strategy (continuing low-/moderate-efficacy DMT vs escalating DMT) were used as covariates in regression analyses.
Results:
A total of 131 patients with RMS, median age of 36 (25th-75th percentiles: 29-43) years, 73% women, were included and observed over a median period of 6 (5-9) years after second MRI. Sixty-two (47%) patients had relapse. Patients who continued first-line DMT had a 3-fold increased risk of relapse given 2 new T2L (hazard ratio [HR] 3.2, lower limit [LL] of 95% CI: 1.5) and a 4-fold increased risk given ≥3 new T2L (HR 4.0, LL-CI: 2.1). Escalation of DMT lowered the risk of relapse in patients with 2 new T2L by approximately 80% (HR 0.2, upper limit [UL] of 95% CI: 1.3) and with ≥3 new T2L by 70% (HR 0.3, UL-CI: 0.8). In case of only 1 new T2L, the increased risk of relapse and the treatment effect did not reach statistical significance of 5%.
Discussion:
In our real-world cohort of patients clinically stable under low-to-moderate-efficacy DMT, escalation of DMT based on isolated MRI activity decreased risk of further relapse when at least 2 new T2L had occurred.
Classification Of Evidence:
This study provides Class III evidence that clinically stable patients with MS on low-/moderate-efficacy DMT with ≥3 new T2L on MRI who escalate DMT have a reduced risk of relapse and Expanded Disability Status Scale progression.
